FDA
-
-
-
-
-
-
-
BTIG Upgrades Moonlake Immunotherapeutics (MLTX) to Buy
-
-
-
-
-
-
-
MoonLake Immunotherapeutics reports mixed phase 3 hidradenitis results
-
-
-
-
-
-
-
Biotech sector Q1 earnings preview from RBC Capital Markets
-
-
-
-
-
-
-
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
-
-
-
-
-
-
-
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for H
-
-
-
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

